MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-02-2026
Xeris Pharmaceuticals ROCE Ratio 2011-2026 | XERS
Annual ROCE Ratio Xeris Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 181.87 | 113.61 | 648.92 | -181.34 | -120.92 | -63.8 | -149.89 | -54.02 | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 648.92 | -181.34 | 46.8 |
Quarterly ROCE Ratio Xeris Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -750.67 | 76.62 | 142.29 | 243.18 | 116.06 | -56.57 | -216.16 | -288.44 | -322.56 | -229.57 | -138.01 | -89.85 | 899.92 | 1923.8 | 1819.72 | 822.39 | 781.68 | -248.79 | -119.13 | -40.71 | -40.71 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1923.8 | -750.67 | 204.02 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.89 | - | 2.43 % | $ 254 M |  Germany |
 |
Arbutus Biopharma Corporation
ABUS
|
-49.83 | $ 4.5 | 0.45 % | $ 862 M |  Canada |
 |
ADC Therapeutics SA
ADCT
|
-48.11 | $ 3.83 | 1.32 % | $ 105 M |  Schweiz |
 |
Agenus
AGEN
|
7.44 | $ 3.64 | 9.31 % | $ 108 M |  USA |
 |
Agios Pharmaceuticals
AGIO
|
-39.57 | $ 35.08 | -0.36 % | $ 2.03 B | USA |
 |
Akebia Therapeutics
AKBA
|
72.06 | $ 1.39 | 0.36 % | $ 357 M | USA |
 |
Akari Therapeutics, Plc
AKTX
|
-60.98 | $ 3.95 | -11.63 % | $ 266 B |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
-49.48 | - | 2.54 % | $ 160 B |  France |
 |
Aldeyra Therapeutics
ALDX
|
-79.69 | $ 1.57 | -5.42 % | $ 94.3 M | USA |
 |
Aligos Therapeutics
ALGS
|
-164.32 | $ 8.08 | 1.38 % | $ 79.9 M | USA |
 |
Biophytis SA
BPTS
|
-325.06 | - | -13.47 % | $ 169 M | France |
 |
Alnylam Pharmaceuticals
ALNY
|
63.56 | $ 331.14 | 3.85 % | $ 43.4 B | USA |
 |
Altimmune
ALT
|
-42.02 | $ 3.4 | 1.8 % | $ 300 M | USA |
 |
ALX Oncology Holdings
ALXO
|
-400.37 | $ 1.99 | 0.81 % | $ 107 M | USA |
 |
Amgen
AMGN
|
104.87 | $ 344.03 | -1.12 % | $ 185 B | USA |
 |
Midatech Pharma plc
MTP
|
-337.43 | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
14.49 | $ 12.27 | -1.68 % | $ 3.85 B | USA |
 |
Anika Therapeutics
ANIK
|
-41.29 | $ 14.99 | 1.28 % | $ 220 M | USA |
 |
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K | USA |
 |
ANI Pharmaceuticals
ANIP
|
0.14 | $ 73.8 | -0.55 % | $ 1.43 B | USA |
 |
Annexon
ANNX
|
-102.25 | $ 5.56 | 1.0 % | $ 862 M | USA |
 |
Annovis Bio
ANVS
|
-176.22 | $ 2.56 | 12.28 % | $ 52.6 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-196.79 | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Applied Molecular Transport
AMTI
|
-209.11 | - | - | $ 10.1 M | USA |
 |
Aprea Therapeutics
APRE
|
-106.37 | $ 0.7 | -1.87 % | $ 4.58 M | USA |
 |
Aquestive Therapeutics
AQST
|
211.07 | $ 4.12 | -0.24 % | $ 441 M | USA |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
64924.32 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-35.64 | $ 8.14 | 1.31 % | $ 223 M |  Israel |
 |
Aeglea BioTherapeutics
AGLE
|
-29.3 | - | - | $ 1.01 B | USA |
 |
Ardelyx
ARDX
|
-24.54 | $ 5.99 | 0.84 % | $ 1.44 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-38.05 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
argenx SE
ARGX
|
-211.69 | $ 749.99 | 0.48 % | $ 25 B |  Niderland |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
Arcutis Biotherapeutics
ARQT
|
-6.45 | $ 24.06 | 1.82 % | $ 3.06 B | USA |
 |
Arvinas
ARVN
|
-27.31 | $ 10.87 | 0.14 % | $ 771 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
8.53 | $ 60.28 | -1.23 % | $ 8.06 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-252.54 | - | 3.16 % | $ 1.9 M | USA |
 |
Assembly Biosciences
ASMB
|
-5.86 | $ 29.51 | 1.72 % | $ 331 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.41 | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-299.27 | - | 10.36 % | $ 9.8 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-104.38 | $ 3.62 | 1.82 % | $ 8.71 B |  Australia |